Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

NCT02846324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis
Hypoxemia

Interventions

DRUG: GBT440
DRUG: Placebo

Sponsor

Global Blood Therapeutics